Quick Answer: Back pain is not a recognized direct side effect of GLP-1 receptor agonists according to FDA prescribing information and clinical trial data
In December 2024, Eli Lilly, the US pharmaceutical giant, announced the launch of its blockbuster drug, Tirzepatide, in India in 2025
[+/-Cl77891 (Titanium Dioxide), Ci 77491 (Iron Oxides)], Mica, Ctearyl Ethylhexanoate, Hdi/Trimethylol Hexyllactone Crosspolymer, Soualane, Octyldodecyl Stearoyl Stearate, Glycerin, Polysorbate 80, Ethylhexylglycerin, Caprylyl Glycol, 1,2-Hexanediol, Synthetic Fluorphlogopite, Chondrus Crispus Extract, Xanthan Gum, Pentaerythrityl Tetra-DiButyl Hydroxyhydrocinnamate, Silica, Dicalcium Phosphate, Tocopherol
Here is how their pricing stacks up against competitors offering similar compounded semaglutide services: Direct Meds falls in the mid-range for pricing
Kandhare, A
Journal of the American Chemical Society